# Microdosing a GLP-1: what it means and what has been tested

Source: https://pepvault.app/guides/microdosing-a-glp-1

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Microdosing a GLP-1: what it means and what has been tested

Reviewed November 2026 18 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

What microdosing semaglutide or tirzepatide means, why no trial has results yet, and what the lowest label doses did in SURMOUNT-MAINTAIN, SUSTAIN and others.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 18
- **Questions:** 6
- **Compounds:** 3

## The short answer

Microdosing a GLP-1 means taking less than the label's lowest step, or spacing shots further apart; it has no medical definition. No trial has reported results: one randomized study is registered, with nothing published as of November 2026. The closest data are label doses: in SURMOUNT-MAINTAIN, people who dropped to tirzepatide 5 mg kept 16.6% weight loss, against 21.9% on 10 or 15 mg. Dose changes are a prescriber's call.

Every number checked at its primary source · Nov 20, 2026 · [18 sources](https://pepvault.app/guides/microdosing-a-glp-1#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** No trial results for microdosing as of November 2026: one registered randomized study without results and one observational cohort. The dose data are from randomized label and dose-finding trials, and the spacing data from one retrospective case series.

## What do people mean by microdosing a GLP-1?

Three different things, and none of them is a medical term. A 2026 review in Minerva Endocrinology defines a microdose as any dose lower than the lowest approved dose, the starting dose on the label[1](https://pepvault.app/guides/microdosing-a-glp-1#source-1). A 2026 commentary in Expert Opinion on Pharmacotherapy describes it as 25 to 50% of the starting dose, or longer gaps between doses[2](https://pepvault.app/guides/microdosing-a-glp-1#source-2). Both papers name counting the clicks of a multi-dose pen's dial as a way people measure the small doses; Ozempic's own instructions say its starter pen delivers doses in 0.25 mg or 0.5 mg increments only[1](https://pepvault.app/guides/microdosing-a-glp-1#source-1) [2](https://pepvault.app/guides/microdosing-a-glp-1#source-2) [4](https://pepvault.app/guides/microdosing-a-glp-1#source-4). Some also use it for staying on the lowest label step for months instead of moving up, a pattern one 2026 records study treats as a possible overlap[9](https://pepvault.app/guides/microdosing-a-glp-1#source-9). Doses below the starting step and stretched gaps are off-label, meaning outside what the prescribing information describes, and the Minerva review notes that no manufacturer, regulator, scientific society or clinical guideline supports them[1](https://pepvault.app/guides/microdosing-a-glp-1#source-1). Staying on the starting step falls outside Zepbound's label, which says 2.5 mg is not approved as a maintenance dosage[5](https://pepvault.app/guides/microdosing-a-glp-1#source-5).

To know what sits below the lowest step, start with the steps themselves. Each label begins low and steps up after at least four weeks on a dose, and each says the climb is there to reduce the risk of gastrointestinal side effects[3](https://pepvault.app/guides/microdosing-a-glp-1#source-3) [4](https://pepvault.app/guides/microdosing-a-glp-1#source-4) [5](https://pepvault.app/guides/microdosing-a-glp-1#source-5) [6](https://pepvault.app/guides/microdosing-a-glp-1#source-6).

| Brand | Starting dose | What the label calls it | Lowest maintenance dose |
| --- | --- | --- | --- |
| Wegovy (semaglutide, weekly shot) | 0.25 mg, weeks 1 to 4 | Starting dosage, followed by escalation to 0.5, 1 and 1.7 mg[3](https://pepvault.app/guides/microdosing-a-glp-1#source-3) | 1.7 mg; 2.4 mg recommended for weight reduction[3](https://pepvault.app/guides/microdosing-a-glp-1#source-3) |
| Ozempic (semaglutide, weekly shot) | 0.25 mg, weeks 1 to 4 | Initiation dosage; the pen table lists 0.25 mg for initiation and 0.5 mg for maintenance[4](https://pepvault.app/guides/microdosing-a-glp-1#source-4) | 0.5 mg[4](https://pepvault.app/guides/microdosing-a-glp-1#source-4) |
| Zepbound (tirzepatide, weekly shot) | 2.5 mg, weeks 1 to 4 | For treatment initiation and not approved as a maintenance dosage[5](https://pepvault.app/guides/microdosing-a-glp-1#source-5) | 5 mg[5](https://pepvault.app/guides/microdosing-a-glp-1#source-5) |
| Mounjaro (tirzepatide, weekly shot) | 2.5 mg | Starting dosage, raised in 2.5 mg steps if more blood-sugar control is needed[6](https://pepvault.app/guides/microdosing-a-glp-1#source-6) | No separate maintenance dose named; maximum 15 mg[6](https://pepvault.app/guides/microdosing-a-glp-1#source-6) |

Retatrutide, the fourth name people pair with microdosing in search, has no label to read a lowest step from: Drugs@FDA lists no approval for it as of November 2026[18](https://pepvault.app/guides/microdosing-a-glp-1#source-18).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault logs each dose as you record it and reminds you on your own schedule, weekly or every two weeks.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Has any trial tested microdosing a GLP-1?

No trial has reported results. We searched ClinicalTrials.gov and PubMed on November 20, 2026, and found two registered studies that use the word, neither with results.

- **AgelessRx, NCT07092605.** The only randomized one: an early phase 1 study at one site, planning 150 healthy adults aged 18 to 65 who want microdoses for health and longevity and do not seek weight loss. They get compounded semaglutide under the tongue, compounded semaglutide by injection, or a placebo, weekly for up to 6 months. Its listed outcomes include self-reported pain, blood counts, basic blood chemistry, mood, heart-rate variability, sleep and activity from wearables. The record gives no dose amount. It started in November 2024 and was registered in July 2025; its estimated primary completion, November 2025, has passed with no results posted, and the record still reads enrolling by invitation, unchanged since July 2025[7](https://pepvault.app/guides/microdosing-a-glp-1#source-7).
- **Noom, NCT07588984.** An observational cohort, so people are not randomly assigned: it follows users of the company's programs, including arms on standard and "microdose" compounded semaglutide and tirzepatide, for up to 24 months. It began recruiting in May 2026 and estimates its primary completion for May 2029[8](https://pepvault.app/guides/microdosing-a-glp-1#source-8).

On microdosing itself, PubMed holds commentaries, letters and reviews, and one records study. It searched 29 million health records for people prescribed only the starting dose at least three times over six months or more: 814 on semaglutide 0.25 mg and 1,016 on tirzepatide 2.5 mg. Their average weight change at 12 months was −2.2% and −5.5%[9](https://pepvault.app/guides/microdosing-a-glp-1#source-9). The authors say this prescribing pattern may overlap with microdosing but does not establish it, and records studies show associations, not causes[9](https://pepvault.app/guides/microdosing-a-glp-1#source-9). The Expert Opinion commentary sums it up: high-quality evidence is essentially absent[2](https://pepvault.app/guides/microdosing-a-glp-1#source-2).

## How much weight did the lowest doses lose in trials?

The nearest real numbers come from trials that compared set doses with placebo, three of them with several doses side by side. Weight loss rose with the dose in all but one step, and even the smallest dose beat placebo.

| Trial | Who | Dose | Weeks | Weight change |
| --- | --- | --- | --- | --- |
| O'Neil 2018, dose-finding[10](https://pepvault.app/guides/microdosing-a-glp-1#source-10) | Obesity, no diabetes | Semaglutide 0.05 / 0.1 / 0.2 / 0.3 / 0.4 mg, injected daily | 52 | −6.0% / −8.6% / −11.6% / −11.2% / −13.8%; placebo −2.3% |
| SUSTAIN 1[11](https://pepvault.app/guides/microdosing-a-glp-1#source-11) | Type 2 diabetes | Semaglutide 0.5 / 1.0 mg weekly (Ozempic's steps) | 30 | −3.7 kg / −4.5 kg; placebo −1.0 kg |
| STEP 1[12](https://pepvault.app/guides/microdosing-a-glp-1#source-12) | Overweight or obesity | Semaglutide 2.4 mg weekly (Wegovy) | 68 | −14.9%; placebo −2.4% |
| SURMOUNT-1[13](https://pepvault.app/guides/microdosing-a-glp-1#source-13) | Obesity or overweight, no diabetes | Tirzepatide 5 / 10 / 15 mg weekly | 72 | −15.0% / −19.5% / −20.9%; placebo −3.1% |

Weight loss rises with the dose in both trials, with one dip (O'Neil's 0.3 mg arm, -11.2%, just under 0.2 mg's -11.6%), and the smallest dose still lost more than placebo. O'Neil's doses are daily, SURMOUNT-1's weekly.

Two cautions in reading it. The O'Neil arms were daily injections, a different schedule from today's weekly pens, so they do not map one to one onto the weekly steps; its 0.3 mg arm lost slightly less than 0.2 mg, and even its smallest arm, 0.05 mg a day, adds up to 0.35 mg a week, above the weekly pens' 0.25 mg start[10](https://pepvault.app/guides/microdosing-a-glp-1#source-10). And the SUSTAIN 1 numbers are kilograms over 30 weeks in people with type 2 diabetes, so they do not line up with the percentage rows[11](https://pepvault.app/guides/microdosing-a-glp-1#source-11). None of these arms was a dose below a label's starting step taken for months; that is exactly the untested part.

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)

## Can a lower dose keep the weight off after losing it?

One trial tested it, at a label dose. In SURMOUNT-MAINTAIN, 441 adults with obesity took tirzepatide for 60 weeks, at the highest dose each tolerated, 10 or 15 mg. Then 378 of them were randomly assigned, without knowing which, to stay on that dose, drop to 5 mg, or switch to placebo for another 52 weeks; from week 84, anyone who regained more than half the lost weight could get rescue tirzepatide[14](https://pepvault.app/guides/microdosing-a-glp-1#source-14).

| Group after week 60 | Weight change from the start, week 112 | Received rescue tirzepatide after regaining more than half the loss |
| --- | --- | --- |
| Stayed on 10 or 15 mg | −21.9% | 8% |
| Dropped to 5 mg | −16.6% | 25% |
| Switched to placebo | −9.9% | 67% |

The gap opens after week 60: the 5 mg line sits between staying on and stopping.

The authors read the 5 mg result as a possible alternative to stopping, adding that individual response varies[14](https://pepvault.app/guides/microdosing-a-glp-1#source-14). Note what it is not: 5 mg is a label maintenance dose, twice the starting step, so the trial says nothing about doses below the label[5](https://pepvault.app/guides/microdosing-a-glp-1#source-5) [14](https://pepvault.app/guides/microdosing-a-glp-1#source-14).

Spacing doses out has smaller evidence. A retrospective case series of 30 patients at one obesity practice, moved from weekly to mostly every-other-week shots at the same dose after their weight plateaued, reported average weight going from 74.1 kg to 72.4 kg over about 36 weeks[17](https://pepvault.app/guides/microdosing-a-glp-1#source-17). With no comparison group, it shows what happened to those 30, not what spacing does. Two randomized trials of stepping down are registered and not yet recruiting: one tapers semaglutide 1.7 mg by 25% every 8 weeks against staying on it, and OFF-RAMP steps semaglutide down to 0.5 mg and tirzepatide to 5 mg every other week, against staying on the full dose or switching to a non-GLP-1 drug[15](https://pepvault.app/guides/microdosing-a-glp-1#source-15) [16](https://pepvault.app/guides/microdosing-a-glp-1#source-16).

## Why do people try smaller doses?

Mostly for the stomach, and for cost. The Expert Opinion commentary lists tolerability, cost and access during shortages as the reasons, with the practice spread through patient communities, telehealth programs and clinicians' anecdotes[2](https://pepvault.app/guides/microdosing-a-glp-1#source-2). The side-effect logic has some trial support: in SUSTAIN 1, nausea was reported by 20% on 0.5 mg, 24% on 1.0 mg and 8% on placebo[11](https://pepvault.app/guides/microdosing-a-glp-1#source-11), and the O'Neil trial called its gastrointestinal effects dose-related[10](https://pepvault.app/guides/microdosing-a-glp-1#source-10). In SURMOUNT-1, adverse events led 4.3% on 5 mg, 7.1% on 10 mg and 6.2% on 15 mg to stop, against 2.6% on placebo[13](https://pepvault.app/guides/microdosing-a-glp-1#source-13).

**Commonly reported:** people describe less nausea and a quieter appetite on small doses, with slower weight loss than on the full steps. The Expert Opinion commentary summarizes early reports the same way, as reduced nausea, better adherence and modest weight loss, from real-world reports rather than trials[2](https://pepvault.app/guides/microdosing-a-glp-1#source-2).

Spacing shots out changes the level more than it sounds. Semaglutide's half-life, the time for the amount in the blood to fall by half, is about one week, and tirzepatide's about five days[3](https://pepvault.app/guides/microdosing-a-glp-1#source-3) [5](https://pepvault.app/guides/microdosing-a-glp-1#source-5). On a one-week half-life, about half a dose is left a week later and about a quarter two weeks later, so an every-other-week rhythm lets the level fall further between shots. The chart shows the build-up on the usual weekly rhythm.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Semaglutide in the library](https://pepvault.app/peptides/semaglutide)

Semaglutide, half-life about one week: every other week, one dose falls to about a quarter before the next shot.

## What should you keep track of if your dose changes?

Whether a dose goes up, down or further apart is a treatment decision for your prescriber, and the trials above are what that conversation can start from. What helps either way is a clear record of what you took and what followed.

- Write down every dose as you actually took it, with the date, so a change is visible against the weeks before it.
- Weigh in on the same day of the week, at the same time, so the trend means something.

<!--promo-->

PepVault logs each dose as you record it and reminds you on your own schedule, weekly or every two weeks. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-microdosing-a-glp-1-inline&mt=8)

<!--/promo-->

<!--promo-->

Its doctor's report puts your doses, weigh-ins and side effects for the protocol on one page to bring to your prescriber. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-microdosing-a-glp-1-inline&mt=8)

<!--/promo-->

In STEP 1, nausea and diarrhea were mostly mild to moderate and eased with time[12](https://pepvault.app/guides/microdosing-a-glp-1#source-12). The labels give one sign to act on at once: severe pain in the stomach area that will not go away, with or without nausea or vomiting, means stopping the drug and calling your healthcare provider right away[3](https://pepvault.app/guides/microdosing-a-glp-1#source-3) [5](https://pepvault.app/guides/microdosing-a-glp-1#source-5).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Infante M et al. Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks. Minerva Endocrinol (Torino). 2026. [PubMed 43021748](https://pubmed.ncbi.nlm.nih.gov/43021748/)
2. Beck H, Clements JN. Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opin Pharmacother. 2026. [PubMed 42788826](https://pubmed.ncbi.nlm.nih.gov/42788826/)
3. Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed, revised June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
4. Ozempic (semaglutide) prescribing information, Novo Nordisk. DailyMed, June 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79)
5. Zepbound (tirzepatide) prescribing information, Eli Lilly. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
6. Mounjaro (tirzepatide) prescribing information, Eli Lilly. DailyMed, revised August 2026. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
7. Effectiveness of microdosed GLP-1 in improving health, quality of life, and longevity measures (AgelessRx). ClinicalTrials.gov NCT07092605. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07092605)
8. GLP-1 medication and behavioral health on weight and metabolic outcomes: FLOURISH and THRIVE cohort study (Noom). ClinicalTrials.gov NCT07588984. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588984)
9. Murugadoss K et al. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biol Methods Protoc. 2026. [PubMed 42857675](https://pubmed.ncbi.nlm.nih.gov/42857675/)
10. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018. [PubMed 30122305](https://pubmed.ncbi.nlm.nih.gov/30122305/)
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017. [PubMed 28110911](https://pubmed.ncbi.nlm.nih.gov/28110911/)
12. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. [PubMed 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. [PubMed 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
14. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026. [PubMed 42119587](https://pubmed.ncbi.nlm.nih.gov/42119587/)
15. Evaluation of a semaglutide dose-tapering regimen for weight-loss maintenance in adults with overweight or obesity. ClinicalTrials.gov NCT07783854. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783854)
16. OFF-RAMP feasibility: a pilot trial comparing off-ramping strategies for maintaining weight loss among adults using incretin-based therapies. ClinicalTrials.gov NCT07832084. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832084)
17. Wong M et al. Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series. Obesity (Silver Spring). 2026. [PubMed 41732031](https://pubmed.ncbi.nlm.nih.gov/41732031/)
18. Drugs@FDA: FDA-approved drugs (searched for retatrutide, November 20, 2026). [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)

Zepbound is the one drug approved for sleep apnea. The SURMOUNT-OSA results, how fast it works, CPAP, and where semaglutide stands, as of November 2026.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)

## Related guides

- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
